European Regenerative Medicines Market size is estimated to exceed USD 32 billion by 2027, according to a latest forecast report by Graphical Research.
Growing research and development by the companies to develop innovative medicine will fortify the market growth. The industry has witnessed significant growth in research funding by several governments. In addition, funding has further allowed organizations to continuous clinical studies for new therapeutic applications as well as novel product development. Strong presence of players in region and high development index in healthcare infrastructure will contribute to the market demand.
High adoption of cell technologies to treat numerous disease conditions will augment the market size. Continuous developments in stem cell applications offering efficient treatment for arthritis, cardiac disorders, cancer and ophthalmological disorders among others has paved the way for industry expansion. Additionally, adoption of novel therapeutic pathways in cell-based therapeutics including use of mesenchymal stem cells in acute respiratory disorders (ARD) will drive the customer preference. Furthermore, numerous advancements in regenerative therapies, mainly in development of biologics, stem cells, tissue engineering and cell-assisted therapies, will propel the overall industry growth.
Tissue engineering segment will witness over 7.5% CAGR during the forecast period attributed to increasing chronic disease burden, trauma injuries and accidents. Growing advancements in 3D tissue engineered products to treat various disease conditions will further boost the industry size. Growing adoption regenerative medicine to treat of cardiac disorders, diabetic foot ulcers, burns and wounds will excel the industry outlook. Furthermore, growing demand for organ transplantation as tissue engineering allows regeneration of patient’s own tissue or organ is forecasted to provide lucrative market demand.
Browse detailed statistical insights from the report, “Europe Regenerative Medicine Market Forecast 2027 By Type (Cell Therapy, Tissue Engineering, Gene Therapy), By Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology), Research Report, Country Outlook (Germany, UK, France, Italy, Spain, Sweden, The Netherlands, Russia, Denmark, Switzerland, Poland, Belgium, Norway, Finland), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
Musculoskeletal segment accounted for more than USD 3 billion revenue in 2020 due to the increasing prevalence of musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis and several orthopedic disorders. Increasing advances in gene therapies, cell therapies in the field of sport medicines and orthopedics is expected to drive the market value.
UK regenerative medicine industry is anticipated to expand at over 20.2% CAGR over the projected timeframe. Prominent industry players are continuously undertaking clinical studies for biologics, stem cell technologies, gene therapies, cellular biology, nanotechnology and chemical biotechnology along with others for advanced regenerative medicines applications. High acceptability of stem cell technology and gene therapy coupled with evolving healthcare infrastructure with favorable spending will enhance the industry expansion in the nation.
European regenerative medicines market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
Europe Market, By Type
- Cell Therapy
- Tissue Engineering
- Gene Therapy
Europe Market, By Application
- Wound Healing
The above information has been provided for the following countries:
- The Netherlands